

Comparison of serum magnesium levels in Pre-eclamptic and Normotensive pregnant Nigerian women

ABSTRACT

Background: Pre-eclampsia is a common medical complication of pregnancy associated with increased maternal and perinatal mortality and morbidity. Its etiology is unknown, although several evidences indicate that deficiency of various nutritional elements might play important role.

Aims: To compare the serum magnesium levels in a group of pre-eclamptic and normotensive pregnant Nigerian women in Jos.

Study design: This was a descriptive cross-sectional study.

Place and Duration of Study: Department of Obstetrics and Gynaecology, Jos University Teaching Hospital, Jos, between May 2011 and April, 2012.

Methodology: We included 50 pre-eclamptic patients and 50 controls in the study. A structured questionnaire was administered directly on each subject. For each recruited pre-eclamptic patient, the next eligible normotensive patient matched for age, occupation, educational status, socioeconomic status, parity and gestational age was recruited as control. Venous blood samples were collected from pre-eclamptic and normotensive pregnant women. The sera samples were analyzed for magnesium using a photometric colorimetric analyzer (*Diagnosticum Zrt; Budapest*). The data were analyzed using Epi info 3.5.1 software (CDC, Atlanta Georgia, USA). Tests of associations were done using Student's t-test and chi square test. P value < 0.05 was considered statistically significant.

Results: Mean serum magnesium level in pre-eclamptic women was 0.89 ± 0.10 mmol/l compared to 1.07 ± 0.12 mmol/l in the normotensive pregnant women ($p = 0.001$). The range of serum magnesium in the pre-eclampsics was $0.73 - 0.96$ mmol/l while that in normotensive pregnancies was $0.95 - 1.26$ mmol/l. In patients with mild pre-eclampsia, the mean serum magnesium was 0.93 ± 0.09 mmol/l while it was 0.81 ± 0.08 mmol/l in those with severe pre-eclampsia ($p < 0.0001$). Also there was an inverse relationship between serum magnesium and systolic blood pressure ($r = -0.404$, $p = 0.004$) as well as serum magnesium and diastolic blood pressure ($r = -0.462$, $p = 0.001$).

Conclusion: Serum magnesium level in pre-eclampsics was significantly lower than those in normotensive pregnant women. This finding supports the hypothesis that hypomagnesaemia may be a contributor to the etiology of pre-eclampsia. Introduction of magnesium supplementation in diet may help reduce the incidence of pre-eclampsia in at risk women.

Keywords: Pre-eclampsia, Serum magnesium, Pregnancy, Nigeria

1. INTRODUCTION

Pre-eclampsia is one of the most common causes of maternal and fetal morbidity and mortality with incidence of between 2 – 8% of pregnancies [1,2,3]. This multi-systemic pregnancy related disorder has been dubbed the “disease of theories” because multiple hypotheses have been proposed to explain its occurrence [4,5]. The pathophysiologic abnormalities of the disorder are numerous but central to them is placental ischaemia leading to the release of circulating factor(s) which cause widespread endothelial cell damage and activation of the coagulation system [6,7].

Despite active research for many years, the aetiology of this disorder remains unknown [6,8,9] although contributory factors include young maternal age, nulliparity, obesity, diabetes mellitus, older maternal age, job stress, multiple pregnancy, molar pregnancy, chronic hypertension, renal diseases, antiphospholipid antibody syndrome, family history of pre-eclampsia, collagen vascular diseases as well as nutritional deficiencies including that of magnesium and calcium [6 – 9]. Clinical features of pre-eclampsia including increased neuromuscular irritability, seizures, vasoconstriction, elevated blood pressure, and increased vascular sensitivity to pressor agents are also characteristic of hypomagnesaemia, all of which respond to magnesium therapy [10,11]. Epidemiological data suggest an inverse correlation between dietary magnesium intake and incidence of pre-eclampsia [5,8,10,12]. Among the advocated modalities of prevention of pre-eclampsia is calcium and magnesium supplementation [8,13].

High rate of pre-eclampsia in developing countries have forced some authors to conclude that malnutrition is a risk factor in aetiology of preeclampsia and implicate it by deficit intake of magnesium, calcium and zinc [14,15]. The identification

that low serum magnesium is a risk factor for developing pre-eclampsia is essential for developing intervention strategies designed to reduce the incidence and complications of pre-eclampsia. While most studies on magnesium levels in pre-eclamptic gestation have occurred in developed nations, there has been paucity of literature in developing nations where most of the maternal deaths from preeclampsia and eclampsia occur [16]. Few data exist regarding serum magnesium levels in pre-eclamptic and normotensive pregnant women in our obstetric population and few studies conducted in Nigeria were mainly in the southern part of the country. It is therefore, pertinent to study the levels of serum magnesium in women with pre-eclampsia and compare with that of normotensive pregnant women in Jos, North-central Nigeria. The findings of the study may be a useful contribution toward health planning with respective to effective interventions for the prevention and control of pre-eclampsia.

2. MATERIAL AND METHODS

2.1. Study Area

This was a hospital-based cross-sectional study conducted in the maternity unit of the Department of Obstetrics and Gynaecology, Jos University Teaching Hospital (JUTH), a tertiary health institution situated in the central part of Jos, Plateau State. JUTH serves as a referral center for neighbouring states of Bauchi, Gombe, Benue, Kogi, Nasarawa, Taraba, Adamawa and parts of Kaduna State.

2.2. Study Population

The study population comprised of 50 women with singleton pregnancy with diagnosis of pre-eclampsia and 50 normotensive pregnant women as controls, both at gestational age greater than 20 weeks. Pre-eclampsia was diagnosed as the occurrence of hypertension with blood pressure of $\geq 140/90$ mmHg in combination with significant proteinuria ($\geq ++$), developing after 20 weeks of gestation in a previously normotensive, non-proteinuric patient. Exclusion criteria included pregnant women with multiple pregnancies, chronic hypertension and renal disease. Informed consent was obtained from the women before recruitment into the study. For each recruited pre-eclamptic patient, the next eligible normotensive patient matched for age, occupation, level of education, socioeconomic status, parity and gestational age was recruited as control.

2.3. Sample size

The sample size was determined using the mean and standard deviation of serum magnesium levels in pre-eclamptics and controls from a previous study [17], a power of 80% and a confidence interval of 95%. The following formula was used for calculation of the sample size [18].

$$2N = \frac{4(Z\alpha + Z\beta)^2 (\sigma_1 + \sigma_2)^2}{\Delta^2}$$

Sample size of 50 (25 cases and 25 controls) were needed for the study, however 100 (50 cases and 50 controls) were recruited.

2.4. Data Collection

The purpose of the study and the procedure were explained to all subjects and data was collected from each of them using interviewer administered questionnaire. Information sought for included socio-demographic and obstetric features of the women. Also documented were their weights and packed cell volumes (PCV). During blood pressure measurement, the woman was rested and seated at a 45 degree. The sphygmomanometer cuff was applied around the upper arm and positioned at the level of the heart. The mercury sphygmomanometer was used for blood pressure measurement and the Korotkoff sound V (disappearance of the sound) was used to obtain the diastolic blood pressure because of its reproducibility. Two blood pressure measurements were taken at least five minutes apart and the average of these was calculated. Urine protein estimation was carried out using dipstick measurement of clean catch mid-stream urine specimen.

Then two millilitres (mL) of blood sample from each subject for magnesium estimation was drawn from the ante-cubital vein and emptied into plain test tubes. Tourniquet was not used as this causes blood stasis as well as hypoxia leading to acidaemia (H^+). This was at minimizing the effect of hydrogen ion (H^+) competing and displacing Mg^{+} ions from the plasma protein binding sites which may lead to increased free plasma magnesium. The blood samples were allowed to clot, sent to the laboratory and the sera were separated by centrifugation for 10 minutes at 3000 rpm into plain tubes and stored at $-20^{\circ}C$ until time of analysis for magnesium.

2.5. Laboratory magnesium estimation

Sera magnesium levels were estimated by photometric colorimetric test for magnesium using a standard kit and Magnesium liquid supplied by *Diagnosticum Zrt; Budapest*. The test principle is the formation of a colored complex when magnesium ion is combined with xylidyl blue under alkaline conditions. The intensity of the developed color is proportional to the magnesium ion concentration of the sample. The reagent is prepared by mixing equal volumes of the TRIS buffer and xylidyl blue. This mixture is stable for three days at room temperature up to 25 °C or for seven days at 2-8 °C. A pipette was used to measure 10 microlitre (0.01 ml) of distilled water (blank) into a test tube and 1 ml of the reagent was added. Another pipette was used to measure 0.01 ml of a standard solution of magnesium (with a known concentration of magnesium) into a second test tube and 1 ml of the reagent was added. Another pipette was used to measure 0.01 ml of serum (sample) into a third test tube and 1 ml of the reagent was also added. Using the spectrophotometer, the absorbance of the sample and the standard solution were read against that of the blank after 5 minutes at a wavelength of 500 nm.

The concentration of serum magnesium was calculated from the formula:

Magnesium concentration (mmol/l) =

$$\frac{\text{absorbance of sample solution}}{\text{absorbance of standard}} \times \text{concentration of standard}$$

This method is highly sensitive as it accurately measured magnesium levels as low as 0.004 mmol/l.

2.6. Statistical methods

All results were transferred to the proforma designed for the study. The data were entered and analyzed using Epi info 3.5.1 software (CDC, Atlanta Georgia, USA). The mean and standard deviation of age, parity, gestational age, weight, systolic blood pressure, diastolic blood pressure were calculated. Tests of associations between serum magnesium levels of subjects from both groups were assessed using student t-test. Categorical variables were compared using the Chi-square test. A value of $P < 0.05$ was considered as significant.

3. RESULTS

One hundred patients were evaluated consisting of 50 pre-eclamptic women (cases) and 50 normotensives (controls). Table 1 depicts the obstetric and socio-Demographic characteristics of pre-eclamptic cases and normotensive controls. The mean age of pre-eclamptic patients was 25.92 ± 5.37 years while that of the control was 25.48 ± 5.41 years ($P = 0.684$). The mean parity for the cases was 0.64 ± 0.96 while that of the control was 0.74 ± 1.03 ($P = 0.408$). The mean gestational age at diagnosis were 36.82 ± 2.75 weeks and 36.72 ± 3.23 weeks respectively for the cases and controls ($P = 0.691$). Also with respect to their educational level and occupation, there was no significant difference between the cases and the controls ($P = 0.369$ and $P = 0.544$ respectively).

Table 2 shows the clinical features and packed cell volume (PCV) among the pre-eclamptic and control groups. The mean weight for the cases and controls were 81.07 ± 19.21 kg and 71.27 ± 9.76 kg respectively ($P = 0.002$). Statistical analysis also showed marked significant difference in the mean systolic and diastolic blood pressures between cases and control.

The mean serum magnesium levels in the pre-eclampsics (cases) was 0.89 ± 0.10 mmol/l while that of the normotensive women (controls) was 1.07 ± 0.12 mmol/l ($P = 0.001$). The range of serum magnesium in the pre-eclampsics was 0.73–0.96 mmol/l while that in normotensive pregnancies was 0.95 – 1.26 mmol/l. Serum magnesium tend to be lower with increasing severity of pre-eclampsia. The mean level of serum magnesium among patients with mild pre-eclampsia was 0.93 ± 0.09 mmol/l while those with severe pre-eclampsia was 0.81 ± 0.08 mmol/l ($p = 0.001$).

Table 3 shows the correlation between serum magnesium level and blood pressure of pre-eclamptic patients. There was a significant inverse relationship between serum level of magnesium and systolic blood pressure ($r = -0.404$, $P = 0.004$) as well as serum magnesium and diastolic blood pressure ($r = -0.462$, $P = 0.001$).

Table 1: Obstetric and socio-demographic characteristics of pre-eclamptic patients (cases) and normotensive pregnant women (control)

Characteristics	Cases (n = 50)	Control (n = 50)	P-value
Age	25.92 ± 5.37	25.48 ± 5.41	0.684
Parity	0.64 ± 0.96	0.74 ± 1.03	0.408
Gestational age	36.82 ± 2.75	36.72 ± 2.80	0.600
Education Level			

Illiterate	2(50.0)	2(50.0)	0.369
Primary	7(77.8)	2(22.0)	
Secondary	21(45.7)	25(54.1)	
Tertiary	20(48.8)	21(51.2)	
Occupation			
Housewife	13(59.1)	9(40.9)	0.544
Student	11(61.1)	7(38.9)	
Trader	3(37.5)	5(62.5)	
Self-employ	12(48.0)	13(52.0)	
Civil servant	11(40.7)	16(59.3)	

Table 2: Clinical characteristics and Packed Cell Volume of the study populations

Characteristics	Cases	Control	P-value
Weight (Kg)	81.07±19.21	71.27±9.76	0.002
Systolic BP	158.20±13.05	106.80±8.19	0.001
Diastolic BP	104.40 ± 9.72	66.20±6.35	0.001
PCV (%)	36.20±2.62	34.24 ± 2.04	0.001

P< 0.05 is considered significant

Table 3: Correlation between Serum Magnesium level and blood pressure of pre-eclamptic patients

Parameter	Correlation coefficient (r)	P
Serum Magnesium (mmol/l)	1.00	-
Systolic blood pressure	-0.404	0.004
Diastolic blood pressure	-0.462	0.001

P< 0.05 is considered significant

4. DISCUSSION

The major finding in this study was that of statistically significant decreased mean serum magnesium among pre-eclamptic patients compared to normotensive women (P = 0.001). This is consistent with previous studies conducted in other parts of Nigeria [4,17,19,20]. Again, it is similar to studies reported from India, Thailand and USA [9,12,21]. However, this is in contrast with studies from other countries [5,22–24] where they found no significant difference in mean serum magnesium between pre-eclampsia and controls. There was significantly lower level of mean serum magnesium in severe pre-eclampsia compared to those with mild disease. This finding is consistent with the study reported from India [9].

The lower levels of serum magnesium found in this study among the pre-eclamptic patients could suggest a possible involvement of magnesium in the pathogenesis of pre-eclampsia. However, this result must be interpreted with caution, because the study did not analyze the dietary intake of pre-eclamptic women to confirm whether or not the reduced levels of magnesium reported is due to nutritional deficiencies. In our environment, diets rich in magnesium including rice, cassava, beans, soya beans, beef, vegetable and yam flour are available. Obviously, most of our staple foods are rich in magnesium [17], therefore dietary deficiency of magnesium being responsible for the low levels of this element among pre-eclamptic patients found in this study is unlikely.

It has been estimated however that magnesium intake has declined by more than half during this century [8], because of reduced magnesium in the ecosystem with resultant poor magnesium content of food items [8,25]. The magnesium content of food is further compromised with overcooking, processing and reprocessing of food products [8,25].

Magnesium has established its role in obstetrics with its relationship to both fetal and maternal wellbeing. The low concentration of magnesium in serum exposes the patient to risk of pregnancy complications including pre-eclampsia and this is usually due to a defect in an enzymatic process which occurs as a result of low circulating magnesium to function as a co-factor [20].

Thus, the success of magnesium therapy for prevention of convulsion in pre-eclamptic patients, as a treatment for eclamptic seizures and its known effect on vascular responses in-vitro suggest that magnesium might be deficient in women with pre-eclampsia [20] as noted in this study. Unavailability of this element due to nutritional deficiency or decrease concentration in the ecosystem may be a predisposing factor in the development of pre-eclampsia or a contributing factor in its pathogenesis [3,8,12,24,26]. The consequences of low magnesium may lead to a reduction in cerebral blood flow, cerebral vasospasm and increase in neuronal burst [8] leading to seizures typically seen in eclampsia, a condition usually preceded by severe pre-eclamptic state. This hypothesis of the role of hypomagnesaemia in pre-eclampsia is also supported by the fact that women with severe pre-eclampsia in this study had significantly lower mean serum magnesium compared to those with mild disease. This suggests that the lower the serum magnesium level, the more severe the pre-eclamptic disease.

Macdonald et al [27] have shown experimentally that magnesium has a vasoprotective effects. And this explains the use of magnesium sulphate as a neuroprotectant and antivasospastic agent in women with pre-eclampsia and eclampsia. Magnesium (mg++) may increase cerebral blood flow and reduce the contraction of cerebral arteries caused by various stimuli [8,27]. The suggested clinical implication of low magnesium seen in our patients may be increased vascular contractility leading to increased blood pressure as noted in this study, low cerebral blood flow and a tendency to eclamptic fits. Physicians now agree that the medication for prevention of seizures in pre-eclampsia and treatment of eclamptic fits is magnesium sulfate [8,21]. The systemic effects of magnesium include vasodilatation and an increase in blood flow and these prevent eclampsia by selectively dilating the cerebral vasculature and relieving the cerebral vasospasm associated with pre-eclampsia. In the eclamptic patient, it will prevent recurrent seizures which are beneficial in reducing the mortality and morbidity in both mother and fetus [8,21]. Other studies have also demonstrated that magnesium has neuro-protective effects as well as protection against vasospasm [8,26]. The consequences of this deficiency may therefore be responsible for the clinical manifestations that are observed in this disease, since magnesium ion is important in cellular and neuronal metabolism as well as cell membrane stability [25].

Magnesium depletion increases the susceptibility of cells to oxidative stress which on its own can affect the cardiovascular system negatively and enhance accelerated atherosclerosis [19]. It is convincing therefore that the vascular syndromes of pre-eclampsia namely pathologic vasospasm, increased peripheral resistance and ischaemic damage may be related to the extracellular magnesium depletion as found in this study. The inverse relationship between serum magnesium and blood pressure noted in this study may explain the pathologic vasospasm usually seen in pre-eclampsia and eclampsia. Despite the suggestion emerging from this study of a role of magnesium in the regulation of blood pressure (BP) in pregnancy and pre-eclampsia, some caution need to be considered. There is the need for longitudinal data obtained serially during pregnancy to ascertain whether or not the development of magnesium depletion necessarily correspond with increasing blood pressure throughout pregnancy and thus in particular, whether pre-eclamptic pregnancies can be distinguished by decreasing serum magnesium before the onset of clinical signs and symptoms.

There is at the moment no reliable marker for pre-eclampsia, though the finding in this study may implies that low level of free magnesium in pre-eclampsia is more than a casual relationship and hypomagnesaemia may in fact be a marker for pre-eclampsia. Recent research studies by other workers have raised the possibility that magnesium supplementation may be useful in the prevention of pre-eclampsia [17,28].

The major limitation of this study is that it did not analyze the dietary intakes of pre-eclamptic and normotensive pregnant women to confirm whether or not the reduced levels of magnesium found in this study was due to nutritional deficiencies in the pre-eclamptics.

5. CONCLUSION

The study shows that mean serum magnesium level in pre-eclamptic women was significantly lower than that in normotensive pregnant women as well as an inverse relationship between serum magnesium and blood pressure among pre-eclamptic women. This finding supports the hypothesis that hypomagnesaemia is a possible contributor to the aetiology of pre-eclampsia, and dietary supplementation of this element may help in preventing pre-eclampsia in women at risk.

6. RECOMMENDATIONS

Dietary supplementation with magnesium enriched diet in at risk patients should be considered as a modality in preventing pre-eclampsia so as to reduce the high mortality and morbidity from the disease. Also, a longitudinal

research is required to estimate the serum magnesium in a cohort of women at risk or among primigravidae before 20 weeks gestation to determine its association with the development of pre-eclampsia.

CONSENT

Informed consent was obtained from the subjects before enrolment into the study.

ETHICAL APPROVAL

Approval for the study was granted by the Research and Ethical Committee of Jos University Teaching Hospital, Jos.

REFERENCES

1. Soydemir F, Kenny L. Hypertension in pregnancy. *Current Obstet Gynaecol* 2006; 16: 315 – 20.
2. Anorlu RI, Iwuala NC, Odum CU. Risk factors for pre-eclampsia in Lagos, Nigeria. *Aust NZ J Obstet Gynaecol* 2005; 45:278 – 82.
3. Walker JJ. Pre-eclampsia. *Lancet* 2000; 356:1260 – 5.
4. Solomon CG, Seely EW. Pre-eclampsia – searching for the cause. *N Engl J. Med.* 2004; 350: 641 – 2.
5. Golmohammad lou S, Amirabi A, Yazdia M, Pashapour N. Evaluation of serum calcium, magnesium, copper and zinc levels in women with pre-eclampsia. *Iran J Med Sci* 2008; 33: 231 – 4.
6. Celik O, Hascalik S, Turkoz Y, Gokdeniz R. Cerebrospinal Fluid nitric oxide level changes in pre-eclampsia. *Eur J Obstet Gynecol Reprod Biol* 2003; 111:141 – 5.
7. Miller DA. Hypertension. In: De Cherney AH, Nathan L, Goodwin TM, Laufer N. (Eds). *Current Diagnosis and Treatment in Obstetrics and Gynaecology*. USA. McGraw Hill Companies, 2007; 318-27.
8. Idogun ES, Imarengiaye CO, Momoh SM. Extracellular calcium and magnesium in pre-eclampsia and eclampsia. *African J Reprod Health* 2007; 2: 80 – 5.
9. Jain S, Sharma P, Kulshreshtha S Mohan G, Singh S. Role of calcium, magnesium and zinc in pre-eclampsia. *Bio Trace Elem Res* 2010; 33: 162 – 70.
10. Resnick LM, Barbagallo M, Bardicef M, Bardicef O, SorokinY, Evelhoch J et al. Cellular – Free magnesium Depletion in Brain and Muscle of Normal and Preeclamptic Pregnancy. *Hypertension* 2004; 44: 322 – 6.
11. Bringman J, Gibbs C, Ahokas R. Differences in serum calcium and magnesium between gravidas with severe pre-eclampsia and normotensive controls. *Am J Obstet Gynecol* 2006; 195: S148.
12. Sukonpan K, Phupong V. Serum Calcium and serum magnesium in normal and pre-eclamptic pregnancies. *Arch Gynecol Obstet* 2005; 273: 12 – 6.
13. Sibai MB, Villar MA, Bray E. Magnesium supplementation during pregnancy. A double – blind study. *Br J Obstet Gynaecol* 1988; 950:120 – 5.
14. Caughey AB, Stotland NE, Washington AE, Eschobar GJ. Maternal Ethnicity, Paternal ethnicity, and parental ethnic discordance. Predictors of pre-eclampsia. *Obstet Gynaecol* 2005; 106: 156 – 6.
15. Priyali P, Umesh K. Role of trace elements zinc, copper and magnesium during pregnancy and its outcome. *Indian J Paediatr* 2004; 71:1003 – 5.
16. A Joint WHO/UNFPA/UNICEF/ World Bank statement in reduction of maternal mortality 1. (WHO Geneva 1999); 9 – 14.
17. Igberaise GO, Ebeigbe PN, Okonta PI, Okpere EE, Gharoro EP. Serum magnesium in Normal and pre-eclamptic gestations in Benin City. *Niger Med J* 2007; 48:21 – 3.
18. Lawrence MF, Curt DF, David LD. Sample size. *Fundamentals of Clinical Trials*. 3rd edition. Springer, 1998; 7:94 – 129.
19. Odigie IP, Anorlu RI, Adesiyun AE, Odum CU. Serum magnesium levels in non-pregnant, pregnant and pre-eclamptic women in Lagos, Nigeria. *Nig Qt J Hosp Med* 2004; 14: 178 – 80.
20. Akinloye O, Oyewale OJ, Oguntibeju OO. Evaluation of trace elements in pregnant women with pre-eclampsia. *Afr J Biotechnol* 2010; 9: 5196 – 202.
21. Shahnaz A, Payam K, Fatemeh G, Anahita M. Serum magnesium and calcium ions in patients with severe pre-eclampsia /eclampsia undergoing magnesium sulphate therapy. *Med Sci Monit* 2007;13: 191 – 4.
22. Mc Carty MF. Magnesium taurate for the prevention and treatment of pre-eclampsia / eclampsia. *Med Hypotheses* 1996; 47:269 – 72.
23. Ludwig S, Gabriele S. Magnesium supplementation in pregnancy. A double blind study. *BJOG* 2005; 95:120 – 5.
24. Handwerker SM, Altura BT, Altura BM. Ionized serum magnesium and potassium levels in pregnant women with preeclampsia and eclampsia. *J Reprod Med*. 1995; 40: 201 – 8.
25. Fawett WJ, Haxby EJ, Male DA. Magnesium: Physiology and pharmacology. *Br J Anaesth* 1999; 83: 302 – 20.
26. Pyne GJ, Cadoux-Hudson TA, Clark JF. Magnesium protection against invitro cerebral vasospasm after subarachnoid haemorrhage. *Br J Neurosurg* 2001; 15: 409 – 15.

- 297 27. Macdonald RL, Curry DJ, Aihara Y, Zhang Z, Jahromi BS. Magnesium and experimental vasospasm. J.
298 Neurosurg 2004; 100: 106 – 10.
299 28. Li S, Tian H. Oral low dose magnesium gluconate preventing pregnancy – induced hypertension. Chang Hua Fu
300 Chan Ko Tsa Chin 1997; 32: 613 – 5.

301
302
303